The FY2023 (Dec) proxy of Pacira BioSciences names 20 peer companies for pay. Among Pacira BioSciences and these peers, CEO pay was 8th highest of 9 and total shareholder return was 6th highest of 9.
8th highest of 9in Pacira BioSciences and its pay peers, FY2023 (Dec) by CEO pay:
$3.1M$17.0M
6th highest of 9in Pacira BioSciences and its pay peers, FY2023 (Dec) by total shareholder return:
$56$250
Pay peer group, FY2023 (Dec) proxy
| United Therapeutics | ||
| Ultragenyx Pharmaceutical | ||
| Ionis Pharmaceuticals | ||
| Halozyme Therapeutics | ||
| Alkermes plc. | ||
| PTC Therapeutics | ||
| Travere Therapeutics | ||
| CareDx | ||
| Acadia Pharmaceuticals | Not disclosed | Not disclosed |
| Amicus Therapeutics, Inc. | Not disclosed | Not disclosed |
| Blueprint Medicines Corporation | Not disclosed | Not disclosed |
| Corcept Therapeutics | Not disclosed | Not disclosed |
| Dynavax Technologies Corporation [img:ic_plus-pn] | Not disclosed | Not disclosed |
| Emergent BioSolutions, Inc. | Not disclosed | Not disclosed |
| Exelixis | Not disclosed | Not disclosed |
| Ironwood Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Natera, Inc. [img:ic_plus-pn] | Not disclosed | Not disclosed |
| Organogenesis Holdings, Inc. | Not disclosed | Not disclosed |
| Sarepta Therapeutics, Inc. [img:ic_plus-pn] | Not disclosed | Not disclosed |
| Supernus Pharmaceuticals | Not disclosed | Not disclosed |
20 companies
PSU comparator group
The companies that relative total shareholder return is measured against for performance stock units.
| S&P Pharmaceuticals Select Industry Index (index) | Not disclosed | Not disclosed |
1 company
Changes by year
FY2024 (Dec) proxy
- AddedAni Pharmaceuticalspay peer groupdue to their revenues and market capitalization now falling significantly outside the peer group criteria
- RemovedEmergent BioSolutions, Inc.pay peer groupdue to their revenues and market capitalization now falling significantly outside the peer group criteria
FY2023 (Dec) proxy
- AddedDynavax Technologies Corporationpay peer groupdue to their revenues or market capitalization now falling significantly outside the peer group criteria
- AddedNaterapay peer groupdue to their revenues or market capitalization now falling significantly outside the peer group criteria
- AddedSarepta Therapeuticspay peer groupdue to their revenues or market capitalization now falling significantly outside the peer group criteria
- RemovedAgios Pharmaceuticalspay peer groupdue to their revenues or market capitalization now falling significantly outside the peer group criteria
- RemovedCoherus BioSciences, Inc.pay peer groupdue to their revenues or market capitalization now falling significantly outside the peer group criteria
- RemovedCollegium Pharmaceuticalpay peer groupdue to their revenues or market capitalization now falling significantly outside the peer group criteria
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.